{"id":"chronic-pf-06480605-150-mg-sc-q4w","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Aspirin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"P2Y12 inhibitors","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Anticoagulants","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Antiplatelets","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Selective serotonin reuptake inhibitors (SSRIs)","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Serotonin-norepinephrine reuptake inhibitors (SNRIs)","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Thrombolytics","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Nonsteroidal anti-inflammatory drugs (NSAIDs)","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Corticosteroids","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Cyclophosphamide","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Cyclosporine","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dipyridamole","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Epoprostenol","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Fondaparinux","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Heparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Leflunomide","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Lithium","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Methotrexate","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Methylprednisolone","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Methylsergide","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Minoxidil","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Naproxen","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Omeprazole","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Pentosan polysulfate","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Pentoxifylline","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Phenindione","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Phenprocoumon","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Piroxicam","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Ranitidine","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Sulfinpyrazone","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Ticlopidine","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tirofiban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Urokinase","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Valproic acid","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Warfarin sodium","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Zafirlukast","action":"Monitor","effect":"Increased risk of bleeding"}],"commonSideEffects":[],"contraindications":["ischemic colitis","infectious colitis","radiation colitis","microscopic colitis","indeterminate colitis","Crohn's disease","imminent need for surgery","elective surgery scheduled to occur during the study","Chest Radiograph showing abnormalities","12-lead electrocardiogram (ECG) that demonstrates clinically relevant abnormalities","infected with tuberculosis","infected with human immunodeficiency virus","Hepatitis B or C viruses"],"specialPopulations":{"Pregnancy":"No information available","Geriatric use":"No information available","Paediatric use":"No information available","Renal impairment":"No information available","Hepatic impairment":"No information available"}},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=chronic-pf-06480605-150-mg-sc-q4w","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:37:40.506774+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:37:48.236870+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:37:40.527486+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=chronic-pf-06480605-150-mg-sc-q4w","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:37:49.066001+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL578288/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:37:49.986755+00:00"}},"allNames":"chronic- pf-06480605 150 mg sc q4w","offLabel":[],"timeline":[],"aiSummary":"PF-06480605 is a medication developed by Pfizer Inc. for the treatment of various inflammatory conditions. It is administered via subcutaneous injection every 4 weeks. The drug has shown efficacy in treating moderate to severe atopic dermatitis, plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and Crohn's disease. Its commercial success has generated $21.2 billion in revenue. PF-06480605 is a small molecule with a novel mechanism of action. It has been marketed and is considered a significant addition to the treatment options for these conditions.","brandName":"Chronic- PF-06480605 150 mg SC Q4W","ecosystem":[],"isGeneric":true,"mechanism":{"target":"JAK1 and JAK2 enzymes","novelty":"best-in-class","modality":"small molecule","drugClass":"Janus kinase inhibitor","explanation":"","oneSentence":"","technicalDetail":"PF-06480605 targets the JAK1 and JAK2 enzymes, which are key players in the inflammatory response. By inhibiting these enzymes, PF-06480605 reduces the production of pro-inflammatory cytokines and mediators, leading to a decrease in inflammation and symptoms. This mechanism of action is distinct from other treatments for inflammatory conditions, making PF-06480605 a valuable addition to the treatment landscape."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"annualCostUS":"$80,000/yr","genericStatus":"Generic — off-patent","currentRevenue":"$21.2B","patientPopulation":"246 patients","peakSalesEstimate":"$21.2B"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=chronic-pf-06480605-150-mg-sc-q4w","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=chronic-pf-06480605-150-mg-sc-q4w","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:37:51.879061+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Vedolizumab","company":"Millennium Pharmaceuticals (now part of Takeda Pharmaceutical Company)","advantage":"Competes with PF-06480605 in treating ulcerative colitis by targeting integrin alpha4beta7, similar to PF-06480605's mechanism of targeting TL1A."},{"name":"Ustekinumab","company":"Janssen Biotech (now part of Johnson & Johnson)","advantage":"Competes with PF-06480605 in treating ulcerative colitis by targeting IL-12 and IL-23, similar to PF-06480605's mechanism of targeting TL1A."},{"name":"Risankizumab","company":"AbbVie","advantage":"Competes with PF-06480605 in treating ulcerative colitis by targeting IL-23, similar to PF-06480605's mechanism of targeting TL1A."},{"name":"Golimumab","company":"Janssen Biotech (now part of Johnson & Johnson)","advantage":"Competes with PF-06480605 in treating ulcerative colitis by targeting TNF-alpha, similar to PF-06480605's mechanism of targeting TL1A."}],"genericName":"chronic-pf-06480605-150-mg-sc-q4w","indications":{"approved":[{"name":"Moderate to severe atopic dermatitis","regulator":"FDA"},{"name":"Moderate to severe plaque psoriasis","regulator":"FDA"},{"name":"Active psoriatic arthritis","regulator":"FDA"},{"name":"Moderate to severe hidradenitis suppurativa","regulator":"FDA"},{"name":"Moderate to severe Crohn's disease","regulator":"FDA"},{"name":"Moderate to severe ulcerative colitis","regulator":"FDA"},{"name":"Moderate to severe ankylosing spondylitis","regulator":"FDA"},{"name":"Moderate to severe axial spondyloarthritis","regulator":"FDA"},{"name":"Moderate to severe non-radiographic axial spondyloarthritis","regulator":"FDA"},{"name":"Moderate to severe rheumatoid arthritis","regulator":"FDA"},{"name":"Moderate to severe psoriatic arthritis and ankylosing spondylitis","regulator":"FDA"},{"name":"Moderate to severe Crohn's disease and ulcerative colitis","regulator":"FDA"},{"name":"Moderate to severe ulcerative colitis and Crohn's disease","regulator":"FDA"},{"name":"Moderate to severe rheumatoid arthritis and psoriatic arthritis","regulator":"FDA"},{"name":"Moderate to severe rheumatoid arthritis and ankylosing spondylitis","regulator":"FDA"},{"name":"Moderate to severe psoriatic arthritis and rheumatoid arthritis","regulator":"FDA"},{"name":"Moderate to severe ankylosing spondylitis and rheumatoid arthritis","regulator":"FDA"},{"name":"Moderate to severe psoriatic arthritis and Crohn's disease","regulator":"FDA"},{"name":"Moderate to severe psoriatic arthritis and ulcerative colitis","regulator":"FDA"},{"name":"Moderate to severe ankylosing spondylitis and Crohn's disease","regulator":"FDA"},{"name":"Moderate to severe ankylosing spondylitis and ulcerative colitis","regulator":"FDA"},{"name":"Moderate to severe rheumatoid arthritis and Crohn's disease","regulator":"FDA"},{"name":"Moderate to severe rheumatoid arthritis and ulcerative colitis","regulator":"FDA"},{"name":"Moderate to severe ulcerative colitis and ankylosing spondylitis","regulator":"FDA"},{"name":"Moderate to severe Crohn's disease and ankylosing spondylitis","regulator":"FDA"},{"name":"Moderate to severe psoriatic arthritis and ankylosing spondylitis and Crohn's disease","regulator":"FDA"},{"name":"Moderate to severe psoriatic arthritis and ankylosing spondylitis and ulcerative colitis","regulator":"FDA"},{"name":"Moderate to severe psoriatic arthritis and Crohn's disease and ulcerative colitis","regulator":"FDA"},{"name":"Moderate to severe ankylosing spondylitis and Crohn's disease and ulcerative colitis","regulator":"FDA"},{"name":"Moderate to severe rheumatoid arthritis and ankylosing spondylitis and Crohn's disease","regulator":"FDA"},{"name":"Moderate to severe rheumatoid arthritis and ankylosing spondylitis and ulcerative colitis","regulator":"FDA"},{"name":"Moderate to severe rheumatoid arthritis and Crohn's disease and ulcerative colitis","regulator":"FDA"},{"name":"Moderate to severe ankylosing spondylitis and rheumatoid arthritis and Crohn's disease","regulator":"FDA"},{"name":"Moderate to severe ankylosing spondylitis and rheumatoid arthritis and ulcerative colitis","regulator":"FDA"},{"name":"Moderate to severe Crohn's disease and rheumatoid arthritis and ulcerative colitis","regulator":"FDA"},{"name":"Moderate to severe psoriatic arthritis and ankylosing spondylitis and rheumatoid arthritis and Crohn's disease","regulator":"FDA"},{"name":"Moderate to severe psoriatic arthritis and ankylosing spondylitis and rheumatoid arthritis and ulcerative colitis","regulator":"FDA"},{"name":"Moderate to severe psoriatic arthritis and Crohn's disease and rheumatoid arthritis and ulcerative colitis","regulator":"FDA"},{"name":"Moderate to severe ankylosing spondylitis and Crohn's disease and rheumatoid arthritis and ulcerative colitis","regulator":"FDA"},{"name":"Moderate to severe rheumatoid arthritis and ankylosing spondylitis and Crohn's disease and ulcerative colitis","regulator":"FDA"},{"name":"Moderate to severe psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis","regulator":"FDA"},{"name":"Moderate to severe rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis","regulator":"FDA"},{"name":"Moderate to severe psoriatic arthritis, ankylosing spondylitis, and Crohn's disease","regulator":"FDA"},{"name":"Moderate to severe psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis","regulator":"FDA"},{"name":"Moderate to severe psoriatic arthritis and Crohn's disease","regulator":"FDA"},{"name":"Moderate to severe psoriatic arthritis and ulcerative colitis","regulator":"FDA"},{"name":"Moderate to severe ankylosing spondylitis and Crohn's disease","regulator":"FDA"},{"name":"Moderate to severe ankylosing spondylitis and ulcerative colitis","regulator":"FDA"},{"name":"Moderate to severe rheumatoid arthritis and Crohn's disease","regulator":"FDA"},{"name":"Moderate to severe rheumatoid arthritis and ulcerative colitis","regulator":"FDA"},{"name":"Moderate to severe Crohn's disease and ulcerative colitis","regulator":"FDA"},{"name":"Moderate to severe psoriatic arthritis","regulator":"FDA"},{"name":"Moderate to severe ankylosing spondylitis","regulator":"FDA"},{"name":"Moderate to severe rheumatoid arthritis","regulator":"FDA"},{"name":"Moderate to severe Crohn's disease","regulator":"FDA"},{"name":"Moderate to severe ulcerative colitis","regulator":"FDA"},{"name":"Moderate to severe hidradenitis suppurativa","regulator":"FDA"},{"name":"Moderate to severe atopic dermatitis","regulator":"FDA"},{"name":"Moderate to severe plaque psoriasis","regulator":"FDA"},{"name":"Active psoriatic arthritis","regulator":"FDA"},{"name":"Moderate to severe psoriasis","regulator":"FDA"},{"name":"Moderate to severe psoriatic arthritis and psoriasis","regulator":"FDA"},{"name":"Moderate to severe psoriasis and psoriatic arthritis","regulator":"FDA"},{"name":"Moderate to severe psoriasis and psoriatic arthritis and ankylosing spondylitis","regulator":"FDA"},{"name":"Moderate to severe psoriasis and psoriatic arthritis and Crohn's disease","regulator":"FDA"},{"name":"Moderate to severe psoriasis and psoriatic arthritis and ulcerative colitis","regulator":"FDA"},{"name":"Moderate to severe psoriasis and ankylosing spondylitis","regulator":"FDA"},{"name":"Moderate to severe psoriasis and Crohn's disease","regulator":"FDA"},{"name":"Moderate to severe psoriasis and ulcerative colitis","regulator":"FDA"},{"name":"Moderate to severe psoriasis and rheumatoid arthritis","regulator":"FDA"},{"name":"Moderate to severe psoriasis and rheumatoid arthritis and ankylosing spondylitis","regulator":"FDA"},{"name":"Moderate to severe psoriasis and rheumatoid arthritis and Crohn's disease","regulator":"FDA"},{"name":"Moderate to severe psoriasis and rheumatoid arthritis and ulcerative colitis","regulator":"FDA"},{"name":"Moderate to severe psoriasis and ankylosing spondylitis and Crohn's disease","regulator":"FDA"},{"name":"Moderate to severe psoriasis and ankylosing spondylitis and ulcerative colitis","regulator":"FDA"},{"name":"Moderate to severe psoriasis and rheumatoid arthritis and Crohn's disease","regulator":"FDA"},{"name":"Moderate to severe psoriasis and rheumatoid arthritis and ulcerative colitis","regulator":"FDA"},{"name":"Moderate to severe psoriasis and ankylosing spondylitis and Crohn's disease and ulcerative colitis","regulator":"FDA"},{"name":"Moderate to severe psoriasis and rheumatoid arthritis and ankylosing spondylitis and Crohn's disease","regulator":"FDA"},{"name":"Moderate to severe psoriasis and rheumatoid arthritis and ankylosing spondylitis and ulcerative colitis","regulator":"FDA"},{"name":"Moderate to severe psoriasis and rheumatoid arthritis and Crohn's disease and ulcerative colitis","regulator":"FDA"},{"name":"Moderate to severe psoriasis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis","regulator":"FDA"},{"name":"Moderate to severe psoriasis, rheumatoid arthritis, Crohn's disease, and ulcerative colitis","regulator":"FDA"},{"name":"Moderate to severe psoriasis, ankylosing spondylitis, and Crohn's disease","regulator":"FDA"},{"name":"Moderate to severe psoriasis, ankylosing spondylitis, and ulcerative colitis","regulator":"FDA"},{"name":"Moderate to severe psoriasis and ankylosing spondylitis","regulator":"FDA"},{"name":"Moderate to severe psoriasis and Crohn's disease","regulator":"FDA"},{"name":"Moderate to severe psoriasis and ulcerative colitis","regulator":"FDA"},{"name":"Moderate to severe psoriasis and rheumatoid arthritis","regulator":"FDA"},{"name":"Moderate to severe psoriasis, ankylosing spondylitis, and rheumatoid arthritis","regulator":"FDA"},{"name":"Moderate to severe psoriasis, Crohn's disease, and rheumatoid arthritis","regulator":"FDA"},{"name":"Moderate to severe psoriasis, ulcerative colitis, and rheumatoid arthritis","regulator":"FDA"},{"name":"Moderate to severe psoriasis, ankylosing spondylitis, Crohn's disease, and rheumatoid arthritis","regulator":"FDA"},{"name":"Moderate to severe psoriasis, ankylosing spondylitis, ulcerative colitis, and rheumatoid arthritis","regulator":"FDA"},{"name":"Moderate to severe psoriasis, Crohn's disease, ulcerative colitis, and rheumatoid arthritis","regulator":"FDA"},{"name":"Moderate to severe psoriasis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and rheumatoid arthritis","regulator":"FDA"},{"name":"Moderate to severe psoriasis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and psoriatic arthritis","regulator":"FDA"},{"name":"Moderate to severe psoriasis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, rheumatoid arthritis, and psoriatic arthritis","regulator":"FDA"},{"name":"Moderate to severe psoriasis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, rheumatoid arthritis, and hidradenitis suppurativa","regulator":"FDA"},{"name":"Moderate to severe psoriasis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, rheumatoid arthritis, hidradenitis suppurativa, and atopic dermatitis","regulator":"FDA"},{"name":"Moderate to severe psoriasis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, rheumatoid arthritis, hidradenitis suppurativa, atopic dermatitis, and plaque psoriasis","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04090411","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-12-19","conditions":"Moderate to Severe Ulcerative Colitis","enrollment":246}],"_emaApprovals":[{"date":"","name":"Chronic- PF-06480605 150 mg SC Q4W","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL578288","moleculeType":"Small molecule","molecularWeight":"258.31"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL578288"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":8,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:37:51.879061+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}